RedChemExpress

Product Data Sheet

BMP-4 Protein, Human (His)

Cat. No.:	HY-P7007A
Synonyms:	rHuBMP-4; BMP-2B
Species:	Human
Source:	E. coli
Accession:	P12644 (S293-R408)
Gene ID:	652
Molecular Weight:	18-21 kDa

AA Sequence SPKHHSQRAR KKNKNCRRHS LYVDFSDVGW NDWIVAPPGY QAFYCHGDCP FPLADHLNST NHAIVQTLVN SVNSSIPKAC CVPTELSAIS MLYLDEYDKV VLKNYQEMVV EGCGCR Biological Activity Measured by its ability to induce alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The ED ₅₀ this effect is 17.27 ng/mL, corresponding to a specific activity is 5.790×10 ⁴ units/mg. Appearance Lyophilized powder. Formulation Lyophilized from a 0.2 µm filtered solution of 50 mM Tris-HCL, 300 mM NaCl, pH 7.4, 5% trehalose, 5% mannitol and 0.01% Tween 80. Endotoxin Level <1 EU/µg, determined by LAL method. Reconstitution It is not recommended to reconstitute to a concentration less than 100 µg/mL in ddH ₂ O. Storage & Stability Storad at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage. Shipping Room temperature in continental US; may vary elsewhere.	PROPERTIES	
SPKHHSQRAR KKNKNCRRHS LYVDFSDVGW NDWIVAPPGY QAFYCHGDCP FPLADHLNST NHAIVQTLVN SVNSSIPKAC CVPTELSAIS MLYLDEYDKV VLKNYQEMVV EGCGCR Biological Activity Measured by its ability to induce alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The ED ₅₀ this effect is 17.27 ng/mL, corresponding to a specific activity is 5.790×10 ⁴ units/mg. Appearance Lyophilized powder. Formulation Lyophilized from a 0.2 µm filtered solution of 50 mM Tris-HCL, 300 mM NaCl, pH 7.4, 5% trehalose, 5% mannitol and 0.01% Tween 80. Endotoxin Level <1 EU/µg, determined by LAL method.	PROPERTIES	
is 17.27 ng/mL, corresponding to a specific activity is 5.790×10 ⁴ units/mg.AppearanceLyophilized powder.FormulationLyophilized from a 0.2 μm filtered solution of 50 mM Tris-HCL, 300 mM NaCl, pH 7.4, 5% trehalose, 5% mannitol and 0.01% Tween 80 or PBS, 300 mM NaCl, pH 7.4, 5% trehalose, 5% mannitol and 0.01% Tween 80.Endotoxin Level<1 EU/μg, determined by LAL method.ReconsititutionIt is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH20.Storage & StabilityStored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.	AA Sequence	QAFYCHGDCP FPLADHLNST NHAIVQTLVN SVNSSIPKAC
Formulation Lyophilized from a 0.2 μm filtered solution of 50 mM Tris-HCL, 300 mM NaCl, pH 7.4, 5% trehalose, 5% mannitol and 0.01% Tween 80. Endotoxin Level <1 EU/μg, determined by LAL method.	Biological Activity	
Final Action Storage & Stability Storage & Stability Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.	Appearance	Lyophilized powder.
Reconsititution It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH ₂ O. Storage & Stability Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.	Formulation	
Storage & Stability Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.	Endotoxin Level	<1 EU/µg, determined by LAL method.
recommended to freeze aliquots at -20°C or -80°C for extended storage.	Reconsititution	It is not recommended to reconstitute to a concentration less than 100 $\mu\text{g}/\text{mL}$ in ddH_2O.
Shipping Room temperature in continental US; may vary elsewhere.	Storage & Stability	
	Shipping	Room temperature in continental US; may vary elsewhere.

DESCRIPTION	
Background	Bone Morphogenetic Protein 4 (BMP-4) is a ligand protein with pleiotropic, belongs to TGFβ family. BMP-4 involves in the
	vasculature circulation and can activate receptors on vascular cells ^[1] . BMP-4/TGFβ signaling can be terminated by inhibitory SMADs including SMAD6 and SMAD7, which are activated and induced by BMP signaling and switch off BMP signaling via multiple mechanisms ^[4] . BMP-4 is widely found in different animals, while the sequence in human is highly similar to Rat (96.81%), and mouse (97.54%).

BMP-4 is expressed by endothelial cells (ECs) in response to hypoxia and promotes vascular SMC proliferation. Therefore it inhibits the proliferation of smooth muscle cells (SMCs) isolated from the proximal pulmonary artery while induces proliferation of SMCs isolated from distal pulmonary arteries^[5]. BMP-4 appears to be a marker and driver of vascular calcification, particularly in atherosclerosis^[6]. BMP-4 induces angiogenesis, endothelial cells (ECs) proliferation, and migration^[7]. BMP-4 is differentially expressed in calcified atherosclerotic plaques^[8], serves as the linkers between atherosclerotic vascular calcification with mechanisms of normal bone formation^[9]. BMP-4 increases plaque formation via their pro-inflammatory and pro-atherogenic effects, promoting oxidative stress, endothelial dysfunction and osteogenic differentiation^[3].

REFERENCES

[1]. Yang P, et al. The role of bone morphogenetic protein signaling in vascular calcification. Bone. 2020 Dec;141:115542.

[2]. Miyazawa K, et al. Regulation of TGF-β Family Signaling by Inhibitory Smads. Cold Spring Harb Perspect Biol. 2017 Mar 1;9(3):a022095.

[3]. Herrera B, et al. A rapid and sensitive bioassay for the simultaneous measurement of multiple bone morphogenetic proteins. Identification and quantification of BMP4, BMP6 and BMP9 in bovine and human serum. BMC Cell Biol. 2009 Mar 19;10:20.

[4]. Yang X, et al. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res. 2005 May 27;96(10):1053-63.

[5]. Scimeca M, et al. Plaque calcification is driven by different mechanisms of mineralization associated with specific cardiovascular risk factors. Nutr Metab Cardiovasc Dis. 2019 Dec;29(12):1330-1336.

[6]. David L, et al. Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine Growth Factor Rev. 2009 Jun;20(3):203-12.

[7]. Dhore CR, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001 Dec;21(12):1998-2003.

[8]. Demer LL, et al. Mechanism of calcification in atherosclerosis. Trends Cardiovasc Med. 1994 Jan-Feb;4(1):45-9.

[9]. Boström K, et al. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993 Apr;91(4):1800-9.

[10]. Xu RH, et al. BMP4 initiates human embryonic stem cell differentiation to trophoblast. Nat Biotechnol. 2002 Dec;20(12):1261-4.

[11]. Hatakeyama Y, et al. Distinct functions of BMP4 and GDF5 in the regulation of chondrogenesis. J Cell Biochem. 2004 Apr 15;91(6):1204-17.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA